Cargando…

Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis

INTRODUCTION: The utility of reassessing anti-cyclic citrullinated peptide (anti-CCP) antibody status later in disease in patients presenting with early undifferentiated inflammatory polyarthritis, particularly in those who test negative for both anti-CCP and rheumatoid factor (RF) at baseline, rema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burr, Marian L, Viatte, Sebastien, Bukhari, Marwan, Plant, Darren, Symmons, Deborah P, Thomson, Wendy, Barton, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446486/ https://www.ncbi.nlm.nih.gov/pubmed/22571727 http://dx.doi.org/10.1186/ar3834

Ejemplares similares

Benefit of early treatment in inflammatory polyarthritis patients with anti–cyclic citrullinated peptide antibodies versus those without antibodies
por: Farragher, Tracey M, et al.
Publicado: (2010)

The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis Register
por: Bukhari, M, et al.
Publicado: (2007)

Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients
por: Viatte, Sebastien, et al.
Publicado: (2012)

Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patients
por: Farragher, Tracey M, et al.
Publicado: (2010)

HLA-DRB1 haplotypes predict cardiovascular mortality in inflammatory polyarthritis independent of CRP and anti-CCP status
por: Sharma, Seema, et al.
Publicado: (2022)

Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis
por: Boire, Gilles, et al.
Publicado: (2005)

The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register
por: Plant, Darren, et al.
Publicado: (2011)

Association Between Genetic Variation in FOXO3 and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis
por: Viatte, Sebastien, et al.
Publicado: (2016)

HLA–DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis
por: Ling, Stephanie F., et al.
Publicado: (2016)

Gastric Adenocarcinoma Presenting as a Rheumatoid Factor and Anti-cyclic Citrullinated Protein Antibody-Positive Polyarthritis: A Case Report and Review of Literature
por: Silvério-António, Manuel, et al.
Publicado: (2021)

Association of the HLA–DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis
por: Farragher, Tracey M, et al.
Publicado: (2008)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
por: Potter, C, et al.
Publicado: (2009)

Pathogenic Role of Circulating Citrullinated Antigens and Anti-Cyclic Monoclonal Citrullinated Peptide Antibodies in Rheumatoid Arthritis
por: Won, Pureun, et al.
Publicado: (2021)

The effect of infliximab on rheumatoid factor and anti-citrullinated cyclic peptide antibodies
por: van Damme, N, et al.
Publicado: (2002)

Anti-Cyclic Citrullinated Peptide Antibodies and Joint Involvement in Behçet's Disease
por: Cho, Sung Bin, et al.
Publicado: (2012)

Anti-cyclic citrullinated peptide antibodies in children with Juvenile Idiopathic Arthritis
por: Hamooda, Mohamed, et al.
Publicado: (2016)

Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis
por: Tebo, Anne E, et al.
Publicado: (2012)

Development of synthetic anti-cyclic citrullinated peptide antibody and its arthritogenic role
por: Kim, Youngkyun, et al.
Publicado: (2015)

Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis
por: El-Banna, Hassan, et al.
Publicado: (2014)

Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies
por: Vignesh, Ammapati Paul Pandian, et al.
Publicado: (2015)

Anti-Cyclic Citrullinated Peptide Antibody and Periodontal Status in Rheumatoid Arthritis Patients
por: Mohamad, Wan Majdiah Wan, et al.
Publicado: (2018)

Anti–Cyclic Citrullinated Peptide Antibody as a Predictor of Rheumathoid Arthritis Complications
por: Mekic, Mevludin, et al.
Publicado: (2020)

Replication of Associations of Genetic Loci Outside the HLA Region With Susceptibility to Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis
por: Viatte, Sebastien, et al.
Publicado: (2016)

Evaluation of Anti-Mutated Citrullinated Vimentin Antibodies, Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Omani Patients with Rheumatoid Arthritis
por: Al-Shukaili, Ahmed, et al.
Publicado: (2012)

The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment
por: Elkayam, Ori, et al.
Publicado: (2010)

Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
por: Abdel Fattah, Nermeen SA, et al.
Publicado: (2009)

Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis
por: Alexiou, Ioannis, et al.
Publicado: (2007)

Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?
por: De Rooy, Diederik PC, et al.
Publicado: (2011)

Clinical significance of anti-cyclic citrullinated peptide antibodies in patients with juvenile rheumatoid arthritis
por: Bo, Li, et al.
Publicado: (2008)

The influence of anti-cyclic citrullinated peptide on anticentromere antibody-positive rheumatoid arthritis patients
por: Jearn, La-He, et al.
Publicado: (2010)

Is Anti-Cyclic Citrullinated Peptide Antibody a Good Value Biomarker for Alzheimer Disease?
por: Meamar, Rokhsareh, et al.
Publicado: (2013)

Anti-cyclic citrullinated peptide antibody is a good indicator for the diagnosis of rheumatoid arthritis
por: Abdul Wahab, Asrul, et al.
Publicado: (2013)

Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity
por: Shafaghi, Afshin, et al.
Publicado: (2014)

Anti-Cyclic Citrullinated Peptide Antibody-Positive Meningoencephalitis in the Preclinical Period of Rheumatoid Arthritis
por: Shibahara, Tomoya, et al.
Publicado: (2016)

Diagnostic Performances of Anti-Cyclic Citrullinated Peptides Antibody and Antifilaggrin Antibody in Korean Patients with Rheumatoid Arthritis
por: Choi, Suk Woo, et al.
Publicado: (2005)

The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome
por: Naseem, H, et al.
Publicado: (2008)

Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study
por: Amezcua-Guerra, Luis M, et al.
Publicado: (2006)

Identification of Natural Bispecific Antibodies against Cyclic Citrullinated Peptide and Immunoglobulin G in Rheumatoid Arthritis
por: Wang, Wei, et al.
Publicado: (2011)

Anti-Cyclic Citrullinated Peptide Antibody Is Associated with Interstitial Lung Disease in Patients with Rheumatoid Arthritis
por: Yin, Yufeng, et al.
Publicado: (2014)

Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease in Women with Rheumatoid Arthritis
por: Rocha-Muñoz, Alberto Daniel, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i3atik8aauav4152oo4br963f3